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Breast cancers with nodal isolated tumour cells (ITC) and micrometastases are categorised
as node-negative and node-positive, respectively, in the tumour node metastasis (TNM)
classification. Two recently published interpretations of the TNM definitions were applied
to cases of low-volume sentinel lymph node (SLN) involvement and their corresponding
non-SLNs for reclassification as micrometastasis or ITC. Of the 517 cases reviewed, 82
had ITC and 435 had micrometastasis on the basis of one classification, and the number
of ITC increased to 207 with 310 micrometastases on the basis of the other. Approximately
24% of the cases were discordantly categorised. The rates of non-SLN metastases associ-
ated with SLN ITCs were 8.5% and 13.5%, respectively. Although the second interpretation
of low-volume nodal stage categories has better reproducibility, it may underestimate the
rate of non-SLN involvement. The TNM definitions of low-volume nodal metastases need
to be better formulated and supplemented with visual information in the form of multiple
sample images.
 2008 Elsevier Ltd. All rights reserved.er Ltd. All rights reserved.
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The prognostic impact of small-volume nodal metastases in
breast cancer is widely debated with several studies and re-
views suggesting at least a minor disadvantage in survival,
and others questioning this.1,2 With the introduction and
acceptance of sentinel lymph node (SLN) biopsy (SLNB)
and the resulting increased histopathological scrutiny of
the SLNs, the identification rate of low-volume metastases
has significantly increased.3 This has resulted in a stage
migration, as many of the former node-negative cases con-
taining occult metastases are now placed into the node-po-
sitive micrometastatic group.4 Because of the statistical
artefacts that such a stage migration may cause and the de-
bated prognostic significance of low-volume metastases, the
pathological tumour node metastasis (pTNM) classification
of malignant tumours and the American Joint Committee
on Cancer (AJCC) staging definitions have split the micro-
metastasis category into two, one consisting of the micro-
metastasis category per se (pN1mi; micrometastases not
larger than 2 mm, but larger than 0.2 mm) and the isolated
tumour cell (ITC) category (pN0(i+) for lesions not larger
than 0.2 mm).5,6
Despite the lack of evidence, the distinction between ITC
and micrometastasis seems important, as it influences the
treatment decisions. Micrometastases are considered true
metastases, and are generally treated as such: i.e. completionTable 1 – Main outlines of the EWGS and TS classification rule
EWGS – Capsular (including intravascular) lesions should be consid
involvement should also be considered as nodal, but lesions
in perinodal fat) should not be recorded as nodal involveme
– Tumour cells (multiple) localised clearly in the parenchyma
micrometastasis (pN1mi) even if they were <0.2 mm and th
according to the first description of the distinction between
– For tumour cells localised in vessels or sinuses, a size not la
not larger than 2 mm makes it micrometastasis (pN1mi).
– In case of multiple foci, only the largest should be conside
– Single tumour cells or clusters arranged in a continuous m
be considered and measured as one focus and characterised
– Cells or clusters arranged in a discontinuous manner (separ
(evenly) in a definable part of the lymph node should also b
– Cells, clusters or foci as defined above, arranged in a discont
if the distance between the clusters or foci is smaller than t
– Cells, clusters or foci as defined above, arranged in a disco
distinct and multiple if the distance between the unevenly
cluster or focus, and should be characterised by the size of t
– In case of doubt the lower category (i.e. ITC) should be giv
TS – The study criteria were based on the concept that ITC and m
cell cluster, regardless of the microanatomic location within
clusters or single cells.
– A cluster is a confluent focus of tumour cells touching other
the microscopic section.
– Clusters or cells separated by a single benign cell or a spa
reaction to the tumour cells has caused the separation.
– Any lesion composed of non-cohesive cells or clusters not
– Any lesion with largest cohesive cellular lesion greater tha
– Mitotic activity (proliferation) is not considered.
– For borderline or indeterminate findings, at the two ends
ITC: Isolated tumour cells; EWGS: European Working Group Study; TS: Taxillary dissection is often recommended for such SLN
involvement, and systemic treatment decisions also consider
patients with SLN micrometastasis as node-positive. On the
other hand, ITCs are generally considered node-negative for
both staging and treatment decisions 2,7,8.
It has been suggested that the distinction between micro-
metastasis and ITC lacks reproducibility.9,10 This is partly due
to the different wording of the two main staging resources:
the International Union Against Cancer (UICC) definitions
suggest some qualitative features such as the assessment of
metastatic activity and extravasation in addition to size for
the distinction between pN1mi and pN0(i+)5,11, whereas the
AJCC definitions6 depend only on size.9 Another cause of
the suboptimal reproducibility is the absence of relevant de-
tails from the definitions, giving rise to different
interpretations.9,12,13
Two different interpretations of the current definitions
of ITC and micrometastasis5,6 were recently reported with
the identical aim of improving the consistency of nodal
staging of breast carcinomas. The European Working Group
for Breast Screening Pathology (EWGBSP) suggested that de-
spite an improvement in reproducibility, the distinction be-
tween ITC and micrometastasis was still suboptimal,9
whereas a recent study resulted in a more consistent clas-
sification.12 However, the latter study allows nodal involve-
ment with a much higher overall volume of tumour cells to
be classified as ITC. Our group sought to analyse the valid-s
ered nodal and any lesion with nodal and simultaneous extranodal
purely outside the lymph node (e.g. in afferent lymphatic channels or
nt.
(and not in the sinuses or vascular spaces) should be considered as
ere was no proliferation or stromal reaction associated with them,
ITC and micrometastasis11.
rger than 0.2 mmmakes the lesion ITC (pN0(i+) and size >0.2 mm but
red.
anner, or separated by only a few cells (e.g. 2–5 cells) distance, should
by its largest dimension.
ated bymore than a few cells distance) but dispersed homogeneously
e considered and measured as one focus.
inuous manner and dispersed unevenly, should be considered as one
he smaller cluster or focus.
ntinuous manner and dispersed unevenly, should be considered as
distributed tumour cells, clusters or foci is greater than the smaller
he largest cluster or focus.
en.
icrometastases were distinguished by the size of the largest tumour
or adjacent to the lymph node, and regardless of the number of
tumour cells. This is determined from the two-dimensional image of
tial gap are measured as separate clusters, except when fibroblastic
greater than 0.2 mm represents ITC.
n 0.2 mm but not greater than 2 mm represents micrometastasis.
of this spectrum, the lower stage category should be selected.
urner study.
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rates of non-SLN metastases associated with small-volume
SLN involvement categorised according to the two different
interpretations.
2. Materials and methods
Members of the EWGBSP were asked to collect SLN cases from
their own archives which met the following criteria: (A) SLN
involvement falling either in the ITC or in the micrometasta-
sis group on the basis of the original report (no macrometas-
tases were allowed in any of the SLNs); (B) Axillary lymph
node dissection with a minimum of 6 non-SLNs removed.
Cases which were originally reported as micrometastatic or
having ITC in the SLN but were considered to be macrometa-
static according to any of the two different understandings of
these categories were also excluded.
An electronic spreadsheet (Microsoft Excel file) was used
to collect the data: the number of SLNs removed, the number
of SLNs involved by micrometastasis on the basis of the origi-
nal report, the number of SLNs involved by ITC on the basis of
the original report, the method of identification of the SLN
involvement (haematoxylin and eosin versus immunohisto-
chemistry), the number of non-SLNs assessed and the num-
ber of non-SLNs involved by metastasis. If the SLN was
involved by both micrometastasis and ITC, and similarly,
when multiple SLNs had nodal deposits of tumour cells, only
the largest lesion was considered.Table 2 – Examples of nodal lesions and their classification as m
of the definitions of these categories
SLN lesion examples Classificatio
according to t
EWGS interpret
Single cell in the afferent lymphatic vessel L1 (not nodal)
Single cell in the capsular lymphatic vessel pN0(i+)
Single cell in a nodal sinus or nodal parenchyma pN0(i+)
Single cluster 60.2 mm in the afferent
lymphatic vessel
L1 (not nodal)
Single cluster 60.2 mm in the capsular
lymphatic vessel
pN0(i+)
Single cluster 60.2 mm in the subcapsular sinus pN0(i+)
Single cluster 60.2 mm in the nodal
parenchyma
pN1mi
Multiple cells or clusters evenly dispersed,
involving an area of the SLN >0.2 mm
(in largest dimension), but with largest
cohesive cellular cluster size 60.2 mm
(no desmoplasia present)
pN1mi or pN1
depending on the
size of the involved
Multiple cells or clusters evenly dispersed,
involving an area of the SLN >0.2 mm
(in largest dimension), but with largest
cohesive cellular cluster size 60.2 mm
(with desmoplasia present)
pN1mi or pN1 depen
the size of the involv
Single cluster 60.2 mm present in the
corresponding areas of two consecutive
sections at >0.2 mm interval
pN1mi
ITC: isolated tumour cell; EWGS: European Working Group Study;9 L1
involvement of lymph nodes in the TNM system; pN1: symbol for (macro)m
lymph node micrometastasis in the TNM system; SLN: sentinel lymph nAfter the collection of the above data, contributors were
asked to reassess each involved SLN from their own institu-
tion and reclassify the nodal lesion according to the EWGBSP
study rules (further referred to as the EWG study, EWGS)9 and
according to the rules of the more recent study first authored
by Turner (further referred to as the Turner study, TS).12 They
were asked to provide the number of SLNs containing micro-
metastasis and ITC, respectively, based on both interpreta-
tions for each case.
Details of the two interpretations were published along
with the studies, but are briefly reproduced in Table 1. Some
specific situations and their interpretations are also pre-
sented in Table 2.
The rates of non-SLN positivity associatedwith SLNmicro-
metastasis and SLN ITC were calculated for the whole series
on the basis of both interpretations. The McNemar test was
used for analysing the differences between the distributions
of the cases and the Pearson chi-square test for the analysis
of any association between the presence of non-SLN metasta-
ses and ITCs in the SLNs. All tests were performed with the
VassarStats software.15
It should be noted that neither the SLNB method nor the
histological assessment of the SLNs was homogeneous for
this study and this reflects common everyday practice and
differences between institutions. However, the method of
SLNB biopsy was validated by completion axillary lymph node
dissection in all centres. In the cases studied, axillary lymph
node dissection (removal of non-SLNs) was performed eithericrometastasis or ITC according to the two interpretations
n
he
ation
Classification
according to the TS
interpretation
Comment
pN0(i+)
pN0(i+) A 3rd interpretation14
would also classify this as L1
pN0(i+)
pN0(i+)
pN0(i+) A 3rd interpretation14
would also classify this as L1
pN0(i+)
pN0(i+)
area
pN0(i+)
ding on
ed area
pN1mi or pN1
depending
on the size of
the involved area
pN0(i+)
: lymphatic invasion in the TNM system; pN0(i+): symbol for ITC
etastasis in 1–3 lymph nodes in the TNM system; pN1mi: symbol for
ode; TNM: tumour node metastasis; TS: Turner study.12
Table 3 – Methods used for the evaluation of the SLNs in the different study sites
Institution
identified by senior
author (number of
cases; number with
non-SLN
involvement)
Number of HE levels per grossly or
intraoperatively negative SLN
(distance between levels)
IHC for cases with negative
SLN findings on HE staining
Non-SLNs evaluation
Bianchi (180; 24) Multilevel till extinction of the tissue
block(s) (0.1 mm)
At multiple levels
(clone AE1/AE3)
Slicing of larger LNs, 3–4 consecutive
HE sections per small LN or per slice;
IHC only in ILC
van Diest (129; 26) Slicing of SLNs, 5 levels through each
tissue block (0.250 mm)
At all levels
(clone CAM5.2 or AE1/AE3)
Slicing of larger LNs, 1 HE section per
small LN or per slice; no IHC
Cserni (89; 14) Multilevel till extinction of the tissue
block(s) (between 0.05 and 0.1 mm or
0.250 mm, depending on the period)
At multiple level using
different pancytokeratin clones
(MNF116, AE1/AE3)
Slicing of larger LNs, 1–3 consecutive
HE sections per small LN or per slice;
no IHC
Regitnig (54; 9) Multilevel till extinction of the tissue
block(s) (0.125 mm)
At multiple levels
(clone MNF116)
Slicing of larger LNs, 2 consecutive HE
sections per small LN or per slice; no
IHC
Foschini (26; 3) Three levels per 2 mm-thick slices
(0.2 mm)
1 level per slice/block
(clone MNF116)
1 HE per lymph node; no IHC
Sapino (14; 4) Multilevel till extinction of the tissue
block(s) (between 0.05 and 0.1 mm
depending on the period)
At multiple levels
(clone KL1 and AE1/AE3)
Slicing of larger LNs, 2–3 consecutive
HE sections per small LN or per slice;
no IHC
Callagy (10; 2) Macroscopic slicing at 2 mm and 3
levels with further levels on equivocal
findings (0.1mm)
Only for HE-negative lobular
carcinomas
Macroscopic slicing at 2 mm and
single level per slice; no IHC
Wells (8; 1) Macroscopic slicing at 2 mm and 3
levels with further levels on equivocal
findings (0.1 mm)
Only for HE-negative lobular
carcinomas
Macroscopic slicing at 2mm and
single level per slice; no IHC
Kulka (7; 2) Multilevel till extinction of the tissue
block (0.250 mm)
One level (clone MNF116) Slicing of larger LNs, 1–3 consecutive
HE sections per small LN or per slice;
no IHC
HE: haematoxylin and eosin; IHC: immunohistochemistry, to demonstrate epithelial markers (generally cytokeratins); LN: lymph node; SLN:
sentinel lymph node.
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done on a selective basis for patients with SLN involvement.
The methods used for the histological evaluation of the SLNs
are briefly summarised in Table 3. In general, it can be stated
that all units used a multilevel assessment for the SLNs, and
the majority (involving 96.5% of the cases) also used immuno-
histochemistry routinely to improve the detection rate of low-
volume metastases if the HE findings were negative. Non-
SLNs were submitted to standard histological assessment
involving the evaluation of one to few HE stained sections
depending on the size of the lymph nodes (Table 3). The two
cases of non-SLN ITC associated with SLN micrometastasis
(according to both readings) were considered non-SLN-
negative.
Contributors evaluated their cases using the circulated
guidance used for the EWGS9 and the training informationTable 4 – Concordance between the ITC and micrometastasis
rules
TS ITC
EWGS ITC 82
EWGS micrometastasis 125
Total 207
ITC: isolated tumour cell; EWGS: European Working Group Study;9 TS: Tuused in the TS.12 Reclassification of the cases reflected the
individual interpretation of the definitions and cases. Some
centres performed a dual reading of the cases, and consensus
ratings were entered in the study. Patient identification was
not included in the study; only anonymous re-evaluation of
the SLNs was carried out without any therapeutic or other
consequence, therefore no ethical permission was deemed
necessary.
3. Results
There were 517 breast cancer cases entered in this study.
These were all originally diagnosed as SLNs affected by either
micrometastasis (n = 421), ITC (n = 58) or a small metastasis,
not otherwise specified (n = 38), as the most significant SLN
lesion; 235 (45%) of these were identified by immunohisto-classification of the cases according to the TS and EWGS
TS micrometastasis Total
0 82
310 435
310 517
rner study.12
Table 5 – Distribution of the non-SLN positive cases between the diagnostic categories of ITC and micrometastasis
according to the two interpretations
EWGS TS
Institution identified
by senior author
Proportion of
non-SLN-positive
cases with SLNs
involved by
micrometastasis
Proportion of
non-SLN-positive
cases with SLNs
involved only by ITC
Proportion of
non-SLN-positive
cases with SLNs
involved by
micrometastasis
Proportion of
non-SLN-positive
cases with SLNs
involved only by ITC
Bianchi 21/149 3/31 10/80 14/100
van Diest 25/113 1/16 22/94 4/35
Cserni 14/75 0/14 9/57 5/32
Regitnig 7/42 2/12 6/35 3/19
Foschini 3/23 0/3 3/18 0/8
Sapino 4/11 0/3 3/7 1/7
Callagy 2/10 0/0 2/8 0/2
Wells 0/6 1/2 0/5 1/3
Kulka 2/6 0/1 2/6 0/1
Total 79/435 (18.2%) 7/82 (8.5%) 57/310 (18.4%) 28/207 (13.5%)
ITC: isolated tumour cell; EWGS: European Working Group Study;9 non-SLN: non-sentinel lymph node; SLN: sentinel lymph node; TS: Turner
study.12
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was only used for case selection, because the definition of ITC
and its distinction from micrometastasis in the TNM system
dates from 199911 and its universal usage in the staging sys-
tem was introduced in January 2003 after the publication of
the 6th edition of the TNM books.5,6 Before this date, ITCs
were generally recorded as micrometastasis.
The median (mean ± standard deviation; range) numbers
of SLNs and non-SLNs in this series were 1 (1.7 ± 1; 1–7) and
15 (15.7 ± 6.4; 6–44), respectively. Of the 517 cases, 85 (16.4%)
had non-SLN involvement.
As expected, many cases that were classified as microme-
tastasis on the original report were reclassified as ITC after
the reassessment of cases according to definitions used for
both studies. This transition was obviously due to the fact
that some of the cases were from before 2003.
The distribution of cases between the two staging catego-
ries of ITC andmicrometastasis according to the two interpre-
tations of these categories is shown in Table 4. The proportion
of SLN cases diagnosed with ITC was greater when diagnosed
according to the TS interpretation (40% versus 16%; McNemar
p < 0.000001). Of the 235 cases identified by means of IHC, a
greater proportion belonged to the micrometastasis category
according to the EWGS rules (178 versus 85).
The metastatic non-SLN rates for the diagnostic categories
and institutions are shown in Table 5. If the SLNs contained
only ITC, the non-SLNs were affected by the metastatic pro-
cess in 7/82 cases (8.5%; 95% CI: 4.2% to 16.6%) according to
the EWGS classification, and in 28/207 cases (13.5%; 95% CI:
9.5% to 18.9%) according to the TS classification. The 5% dif-
ference (95% CI: )4.0% to 11.9%) of these proportions was
not significant (z-ratio: )1.172; Pearson p = 0.24).
4. Discussion
The distinction between the ITC and micrometastasis
categories of the pTNM system is also a distinction betweennode-negative and node-positive status.16 As such it may im-
pact upon decisions concerning completion axillary dissec-
tion and systemic adjuvant treatment.2
The main purposes and probably advantages of introduc-
ing the ITC category at the lower end of micrometastasis were
1. to avoid the stage migration arising from more thorough
pathological assessment of SLNs; 2. to account for possible
artefacts of passive tumour cell transport to the SLNs during
preoperative biopsy, localisation procedures, breast massage
or the operative trauma itself and 3. to prevent overtreatment
of low-volume nodal involvement in the light of the disputed
prognostic significance of micrometastatic disease.
Since the definition of ITC is more restrictive according to
the EWGBSP interpretation, and some lesions are obviously
discordantly categorised (Table 2), it is not surprising that
the rate of micrometastasis was higher according to the
EWGS classification.
One of the main advantages of the TS interpretation of the
staging definitions seems to be its reproducibility. When as-
sessed on the basis of digital images, expert breast patholo-
gists were able to achieve a consistent classification of the
nodal lesions (kappa: 0.92).12 In contrast, the EWGBSP
achieved a worse interobserver agreement amongst both ex-
pert breast pathologists (kappa: 0.49)9 and community hospi-
tal-based pathologists (kappa: 0.47).10 A probable explanation
for the differences in reproducibility might be that the TS
classification is simpler, as it is based only on the simple size
criteria, but another factor may be the fact that this interpre-
tation was aided by a series of visual examples. Although
reproducibility was not retested, it is likely that the men-
tioned kappa values characterise the classifications in this
study too.
In contrast, one of the disadvantages of the TS interpreta-
tion seems to be the virtual downstaging of rather high-vol-
ume metastases as ITC. Lobular carcinomas are often
associated with a specific pattern of nodal infiltration, namely
the presence of multiple discohesive cells in the lymph node
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with desmoplasia and are therefore, with a few exceptions,
labelled as ITC according to TS, with a possible comment that
the pN categorisation does underestimate the nodal meta-
static load. Indeed, the TS categorisation would not reflect
the total volume of nodal involvement, which seems an
important factor determining the prognostic impact of nodal
metastases. The TS system would also allow some macrome-
tastases (according to the EWGS understanding17) to be put
into the ITC or at best into the micrometastatic category as
exemplified by Fig. 1 of the TS publication.12 Other tumour
types which may be similarly virtually downstaged would in-
clude tubular carcinomaswith tubules not larger than 0.2 mm
infiltrating the nodal parenchyma without desmoplasia and
micropapillary carcinomas with multiple close but separate
inside out clusters without desmoplasia.
The prognostic effects of the differences in classifications
cannot be assessed in the short term, but current axillary
treatment decisions can be somewhat better monitored. It is
estimated that around 15% of the SLNs with micrometastatic
disease and about 9–10% of the cases with ITC in the SLNs are
associated with non-SLN involvement.18 Although microme-
tastases are sometimes disregarded, and some studies sug-
gest that axillary dissection may be omitted if the SLN
contains only micrometastatic disease,19–21 it is common to
perform completion axillary dissection with this finding.2,7,8
On the other hand, many patients with SLNs affected only
by ITC did not undergo an axillary dissection after the valida-
tion phase, and this may represent some selection bias, due
to the lower than possible percentage of cases with ITC.
Another possible disadvantage of the classification used in
the TS is that it seemed to increase not only the rate of ITC
but also the rate of ITC associated non-SLN metastases. Our
study demonstrates that the rate of non-SLN metastasis is
somewhat higher with the TS approach than with the EWGS
approach (13.5% versus 8.5%), although this difference did not
prove to be statistically significant. Therefore, despite better
reproducibility, the interpretation of the ITC and micrometas-
tasis definition according to the TS may (to a minor extent)
fail to achieve one of the aims of the segregation of the former
micrometastatic category into a node-negative and a node-
positive subgroup as it seems to perform somewhat less per-
fectly in identifying a minimal risk ITC category. In contrast,
the EWGS classification rules put more patients into the
micrometastatic category, and therefore probably increase
the upstaging that the introduction of the ITC category was
designed to prevent. However, with a restrictive approach to
the ITC diagnostic category, it may be possible to separate
cases which are associated with a somewhat lower risk of
non-SLN metastasis, and can therefore more optimally be
considered node-negative, i.e. pN0(i+).
Our study evaluated two different understandings of the
staging categories of ITC and micrometastasis in breast can-
cer patients. However, there are probably other interpreta-
tions (Table 2) 13 and obviously many different practices of
SLN examination as highlighted in a questionnaire-based
study by the EWGBSP.22 With different histology protocols,
different rates of low-volume metastasis will be discovered
in the SLNs, but none of the workable conventional histology
protocols will disclose all ITCs, as these are relatively ran-domly distributed within the SLNs. On the other hand, an al-
most complete detection of micrometastatic disease can be
targeted by several histological protocols.
Considering our results, it is likely that publications such
as the French multi-centre study23 or the report from the
European Institute of Oncology24 suggesting high rates (16%
and 15%, respectively) of non-SLN metastasis associated with
SLN ITCs used a less restrictive interpretation of the defini-
tions for ITC and/or a less rigorous measurement. Indeed,
accurate size was available only in 70% of the cases of the
French study23 and Viale from the European Institute of
Oncology does not take into consideration the location of
the tumour cells in the lymph node when distinguishing be-
tween ITC and micrometastasis.13 Similar interpretation is-
sues may bias the results of any studies dealing with the
possible prognostic effect of low-volume nodal involvement,
as well as its impact on the recommendations for locoregion-
al therapy. It should not be forgotten that other factors such
as tumour size and lymphovascular invasion also influence
the rate of non-SLN positivity.25–27 It is likely that the results
of the American College of Surgeons Oncology Group – Z10
trial and possibly some other American results reflect the
TS interpretation, whereas some European results are more
likely to reflect the EWGS understanding of the ITC versus
micrometastasis distinction. Caution is, therefore, mandatory
when assessing results published in this field and care should
be taken if the results are wildly contradictory; the study pop-
ulations (cases), the definitions (or their interpretation) or the
methods may be different and this may lie behind the dis-
crepancy. Although there are cases of nodal involvement
which are obviously categorised the same way by all patholo-
gists, there are also cases that cannot be classified unani-
mously using the current TNM definitions of staging
categories. Indeed, pathological nodal staging (pN categorisa-
tion) is the translation of the microscopic visual input into the
diagnostic categories defined in the staging manuals.5,6
Therefore, the publications would be greatly enhanced by vi-
sual examples of the written definitions. The lack of such vi-
sual examples may be an important factor contributing to the
mediocre interobserver agreement achieved in the EWGS and
the variability in interpretation that the worded definitions al-
low. Although two ways of interpreting these definitions were
tested in this work, Table 2 alludes to another discordant
interpretation by experts, namely the presence of tumour
cells in the capsular lymphatics of the lymph node which
would not be interpreted as nodal lesions.14 Another article
expressing what 6 European expert pathologists meant by
ITC also suggests minor differences in understanding and
therefore classification.13
In keeping with the conclusions of both studies testing
the reproducibility of the ITC and micrometastasis categories
in breast cancer SLNs,9,12 the authors highlight that the pres-
ent definitions of these staging subgroups are not sufficiently
formulated and do not allow a reproducible classification in
about 24% of the cases. Despite better reproducibility found
in the TS, we demonstrate that classifying nodal involve-
ment according to the definitions used in that study may,
to a minor extent, increase the rate of ITC associated non-
SLN involvement, and therefore may virtually increase the
false-negative (negative SLN associated positive non-SLN)
E U R O P E A N J O U R N A L O F C A N C E R 4 4 ( 2 0 0 8 ) 2 1 8 5 –2 1 9 1 2191rate of SLNB. Both the simplicity and the visual examples
aided the better interobserver agreement in the pN classifi-
cation of SLN findings, but this potential drawback must be
considered before rewording the definitions. The EWGBSP
interpretation of low-volume nodal metastases seems to bet-
ter discriminate between lesions with a lower and higher
risk of non-SLN involvement. Its less than optimal interob-
server agreement could probably also be improved by sample
images.
Neither of the two interpretations of the arbitrarily set
low-volume pN categories may be ideal. About a quarter of
the cases may be differently staged by one or the other, and
this may prevent reliable staging and prognostic conclusions.
As visual examples using sample images may improve the
definitions and their interpretation, as shown by the TS,
whatever modification the TNM endorses in its next update,
such images should not be omitted.
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